| Id |
Subject |
Object |
Predicate |
Lexical cue |
| TextSentencer_T1 |
0-96 |
Sentence |
denotes |
Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. |
| T1 |
0-96 |
Sentence |
denotes |
Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. |
| T1 |
0-96 |
Sentence |
denotes |
Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. |
| TextSentencer_T2 |
97-175 |
Sentence |
denotes |
Ovarian cancer is the fourth most common cancer in women in the Western world. |
| T2 |
97-175 |
Sentence |
denotes |
Ovarian cancer is the fourth most common cancer in women in the Western world. |
| T2 |
97-175 |
Sentence |
denotes |
Ovarian cancer is the fourth most common cancer in women in the Western world. |
| TextSentencer_T3 |
176-339 |
Sentence |
denotes |
In a pilot scale study, we highlight changes in the total serum glycome of patients with advanced ovarian cancer that might shed insight into disease pathogenesis. |
| T3 |
176-339 |
Sentence |
denotes |
In a pilot scale study, we highlight changes in the total serum glycome of patients with advanced ovarian cancer that might shed insight into disease pathogenesis. |
| T3 |
176-339 |
Sentence |
denotes |
In a pilot scale study, we highlight changes in the total serum glycome of patients with advanced ovarian cancer that might shed insight into disease pathogenesis. |
| TextSentencer_T4 |
340-469 |
Sentence |
denotes |
These changes include increases in levels of core fucosylated, agalactosyl biantennary glycans (FA2) and sialyl Lewis x (SLe(x)). |
| T4 |
340-469 |
Sentence |
denotes |
These changes include increases in levels of core fucosylated, agalactosyl biantennary glycans (FA2) and sialyl Lewis x (SLe(x)). |
| T4 |
340-469 |
Sentence |
denotes |
These changes include increases in levels of core fucosylated, agalactosyl biantennary glycans (FA2) and sialyl Lewis x (SLe(x)). |
| TextSentencer_T5 |
470-695 |
Sentence |
denotes |
To investigate further which proteins contribute to these alterations, we developed technology to analyze simultaneously the glycosylation of protein glycoforms contained in single spots excised from a 2D gel (<1 ng protein). |
| T5 |
470-695 |
Sentence |
denotes |
To investigate further which proteins contribute to these alterations, we developed technology to analyze simultaneously the glycosylation of protein glycoforms contained in single spots excised from a 2D gel (<1 ng protein). |
| T5 |
470-695 |
Sentence |
denotes |
To investigate further which proteins contribute to these alterations, we developed technology to analyze simultaneously the glycosylation of protein glycoforms contained in single spots excised from a 2D gel (<1 ng protein). |
| TextSentencer_T6 |
696-872 |
Sentence |
denotes |
The acute-phase proteins, haptoglobin, alpha1-acid glycoprotein, and alpha1-antichymotrypsin from patients contained elevated levels of subsets of glycoforms containing SLe(x). |
| T6 |
696-872 |
Sentence |
denotes |
The acute-phase proteins, haptoglobin, alpha1-acid glycoprotein, and alpha1-antichymotrypsin from patients contained elevated levels of subsets of glycoforms containing SLe(x). |
| T6 |
696-872 |
Sentence |
denotes |
The acute-phase proteins, haptoglobin, alpha1-acid glycoprotein, and alpha1-antichymotrypsin from patients contained elevated levels of subsets of glycoforms containing SLe(x). |
| TextSentencer_T7 |
873-993 |
Sentence |
denotes |
We also established that IgG heavy chains from patients contained twice the level of FA2 compared with healthy controls. |
| T7 |
873-993 |
Sentence |
denotes |
We also established that IgG heavy chains from patients contained twice the level of FA2 compared with healthy controls. |
| T7 |
873-993 |
Sentence |
denotes |
We also established that IgG heavy chains from patients contained twice the level of FA2 compared with healthy controls. |
| TextSentencer_T8 |
994-1149 |
Sentence |
denotes |
Serum CA125 is the only biomarker that is used routinely, and there is a need for complementary markers that will improve both sensitivity and specificity. |
| T8 |
994-1149 |
Sentence |
denotes |
Serum CA125 is the only biomarker that is used routinely, and there is a need for complementary markers that will improve both sensitivity and specificity. |
| T8 |
994-1149 |
Sentence |
denotes |
Serum CA125 is the only biomarker that is used routinely, and there is a need for complementary markers that will improve both sensitivity and specificity. |
| TextSentencer_T9 |
1150-1426 |
Sentence |
denotes |
There was some preliminary indication that combinations of changes in the serum glycome might improve the separation of ovarian cancer and benign tumors; however, a larger study using data receiver operating characteristic curves will be required to draw any firm conclusions. |
| T9 |
1150-1426 |
Sentence |
denotes |
There was some preliminary indication that combinations of changes in the serum glycome might improve the separation of ovarian cancer and benign tumors; however, a larger study using data receiver operating characteristic curves will be required to draw any firm conclusions. |
| T9 |
1150-1426 |
Sentence |
denotes |
There was some preliminary indication that combinations of changes in the serum glycome might improve the separation of ovarian cancer and benign tumors; however, a larger study using data receiver operating characteristic curves will be required to draw any firm conclusions. |